高剂量表柔比星、氯尼达明、α2b干扰素治疗晚期乳腺癌的II期研究。

Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.

作者信息

Iaffaioli R V, Tortoriello A, Facchini G, Santangelo M, Bucci L, Fei L, Di Martino N, Mantovani G, Caponigro F

机构信息

Istituto di Medicina Interna, Universitá di Cagliari, Italy.

出版信息

Breast Cancer Res Treat. 1995 Sep;35(3):243-8. doi: 10.1007/BF00665975.

DOI:10.1007/BF00665975

PMID:7579494

Abstract

44 patients with advanced breast cancer were treated with high-dose epirubicin (130 mg/sqm), because of its steep dose-response curve. Lonidamine and alpha interferon were administered as well with the aim of increasing epirubicin uptake and overcoming drug resistance. Granulocyte-colony stimulating factor support was provided. 14 complete responses and 22 partial responses were observed in 40 evaluable patients for a 90% overall response rate. Median duration of response was 12 months for complete responders, 7 months for partial responders. In two cases the complete response has lasted for more than two years. Myelosuppression, infection, and cardiac toxicity were the main treatment-related toxic effects. These results are encouraging enough to justify a randomized comparison of our chemotherapy program with standard regimens used in advanced breast cancer.

摘要

44例晚期乳腺癌患者接受了高剂量表柔比星（130mg/m²）治疗，因其剂量反应曲线陡峭。同时给予氯尼达明和α干扰素，目的是增加表柔比星的摄取并克服耐药性。提供了粒细胞集落刺激因子支持。在40例可评估患者中观察到14例完全缓解和22例部分缓解，总缓解率为90%。完全缓解者的中位缓解持续时间为12个月，部分缓解者为7个月。有2例完全缓解持续了两年多。骨髓抑制、感染和心脏毒性是主要的治疗相关毒性反应。这些结果足以令人鼓舞，有理由将我们的化疗方案与晚期乳腺癌常用的标准方案进行随机对照比较。